Clinical Trial Update: Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial evaluating fixed-dose vortioxetine with fluoxetine for major depressive disorder in adolescents aged 12-17; study completed with posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Fluoxetine (Fluoxetine)
• Vortioxetine (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED | Results posted: 2020-08-19